The assay, which has previously received patents in Europe and Japan, is based on induced pluripotent stem (iPS) cell technology. Axiogenesis has developed the ability to induce HCM in iPS cell-derived cardiomyocytes, creating an in vitro model of the disease that can be used to evaluate drug candidates and molecular targets.
“There is a great unmet need for better treatments of HCM; however, development of new therapies within pharmaceutical companies requires an enormous amount of time and expense”, said Axiogenesis’ CEO, Dr. Heribert Bohlen, MD. “We estimate that this new technology will help pharma companies bring innovative treatments of HCM to the market in nearly half the time, and with huge cost savings.”
The patent is far-reaching and broadly covers mechanisms for inducing cardiac hypertrophy in any stem cell-derived cardiomyocytes, including Axiogenesis’ Cor.4U® human iPS cell-derived cardiomyocytes and Cor.At® murine stem cell-derived cardiomyocytes.
More information: http://www.businesswire.com/news/home/20121204005099/en
-
font size
decrease font size
increase font size
Friday, 04 January 2013 19:42
Axiogenesis Earns U.S. Patent with In Vitro Drug Discovery Assay for Hypertrophic Cardiomyopathy Featured
The United States Patent and Trademark Office (USPTO) approved a patent for Axiogenesis AG for the invention of its in vitro assay to screen pharmaceutical drug candidates for effectiveness and safety in treating Hypertrophic Cardiomyopathy (HCM).
Dr. rer. nat.
Menschen für Tierrechte - Tierversuchsgegner Rheinland-Pfalz e.V.